A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

General Inclusion Criteria

- Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1

- Life expectancy greater than or equal to 3 months

- Histologically or cytologically confirmed metastatic, non-squamous or squamous
Non-Small Cell Lung Cancer (NSCLC)

- Measurable disease (at least one target lesion)

- Adequate hematologic and end-organ function

- Tumor accessible for biopsy

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures as outlined for each specific
treatment arm

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures, and agreement to refrain from donating sperm, as outlined for
each specific treatment arm

Inclusion Criteria for Cohort 1

- No prior systemic therapy for metastatic NSCLC

- High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) >= 50%

Inclusion Criteria for Cohort 2

- Disease progression during or following treatment for metastatic or locally advanced,
inoperable NSCLC

Exclusion Criteria

- Prior allogeneic stem cell or solid organ transplantation

- Current treatment with anti-viral therapy for hepatitis B virus (HBV)

- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
drainage procedures (once monthly or more frequently)

- Symptomatic, untreated, or actively progressing central nervous system (CNS)
metastases

- History of leptomeningeal disease

- Active or history of autoimmune disease or immune deficiency

- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of
active pneumonitis on screening chest computed tomography scan

- History of malignancy other than NSCLC within 2 years prior to screening

- Active tuberculosis

- Severe infection within 4 weeks prior to initiation of study treatment